Denali Therapeutics
DNLI
#3992
Rank
ยฃ2.16 B
Marketcap
ยฃ14.77
Share price
-1.35%
Change (1 day)
-24.57%
Change (1 year)

Revenue for Denali Therapeutics (DNLI)

Revenue in 2025 (TTM): N/A

In 2024 the company made a revenue of N/A a decrease over the revenue in the year 2023 that were of ยฃ0.25 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Denali Therapeutics from 2017 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) N/A
2024 N/A-100%
2023 ยฃ0.25 B189.38%
2022 ยฃ89.65 M148.7%
2021 ยฃ36.04 M-85.36%
2020 ยฃ0.24 B1110.41%
2019 ยฃ20.34 M-80.01%
2018 ยฃ0.10 B
2017 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Novocure
NVCR
ยฃ0.48 BN/A Jersey
Novavax
NVAX
ยฃ0.76 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Organovo
ONVO
ยฃ0.1 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Orchard Therapeutics
ORTX
ยฃ16.37 MN/A๐Ÿ‡ฌ๐Ÿ‡ง UK